A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2023-08-14
AEs
4
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-03 (study day 98); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-18 (study day 113); relationship: N
severe
serious
assessed
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-30 (study day 125); relationship: not assessed; serious criteria: hospitalization
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-03-16 (study day 202); relationship: not assessed
Data queries
No data queries.